The role of antiviral treatment in acute hepatitis B

Yang Chih Cheng, Sheng Uei Fang, Cheng Tiong, Ching Ruey Hsieh, Horng Yuan Lou, Jean Dean Liu, Shiann Pan, Chun Chao Chang

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)

摘要

Acute hepatitis B was decreasing after the policy of global hepatitis B virus (HBV) vaccination in Taiwan. However, sporadic cases of acute hepatitis B were still encountered in our daily practice. Non-vaccination, non-response or poor response to current hepatitis B vaccine may be the cause. In addition, immune-selected or antiviral selected mutant strain may also cause new HBV infection in post-vaccination era. Studies for acute hepatitis B are not as much as for chronic hepatitis B. What is the role of antiviral agent in treating acute hepatitis B? Articles involved antiviral treatments for acute hepatitis B were reviewed. These studies showed antiviral agent may be beneficial in severe acute hepatitis B. But antiviral agent may play no role for non-severe form because it may interfere normal immune reaction and also impair anti-HBs formation.

原文英語
頁(從 - 到)99-105
頁數7
期刊Journal of Internal Medicine of Taiwan
22
發行號2
出版狀態已發佈 - 4月 2011

ASJC Scopus subject areas

  • 內科學

指紋

深入研究「The role of antiviral treatment in acute hepatitis B」主題。共同形成了獨特的指紋。

引用此